Highest-materiality recent filing
Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend
Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.
Nautilus regains Nasdaq minimum bid price compliance; deficiency closed
Received notice on Nov 3, 2025 that closing bid price met $1 for 10 consecutive days.
Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone
Operating expenses $17.1M, down 18% YoY from $20.8M.
Received notice on May 1, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days through April 30, 2025.
Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
Max materiality 0.75 · Median 0.50 · Most common event earnings